Loading
Weiguo Su led the Shanghai chemistry that produced fruquintinib, savolitinib and surufatinib, three Chinese-discovered cancer pills approved at home and, for fruquintinib, in the US.
A former Pfizer chemist who joined Hutchmed in 2005 as head of research and became CEO in 2022; his team designed fruquintinib (FDA approval 2023 via Takeda), the selective MET inhibitor savolitinib (partnered with AstraZeneca) and surufatinib, the first Chinese-discovered small molecules to reach global markets.
Shares Hutchmed and the tag china.
Shares Savolitinib, Hutchmed.
Shares Hutchmed and the tag china.
Shares Hutchmed, Fruquintinib.
Shares Savolitinib, Hutchmed.
Shares Savolitinib, Hutchmed.
Shares Hutchmed, Fruquintinib.
Shares Hutchmed, Fruquintinib.